Abstract
We determined the amount of tamoxifen, N-desmethyltamoxifen (metabolite X), N-desdimethyltamoxifen (metabolite Z), and hydroxylated metabolites (Y, B, BX) in brain metastases from breast cancer and in the surrounding brain tissues. Specimens were collected from the breast cancer patients who received tamoxifen for 7-180 days and with the last dose taken within 28 h before surgical removal of the tumour. The concentrations of tamoxifen and its metabolites were up to 46-fold higher in the brain metastatic tumour and brain tissue than in serum. Metabolite X was the most abundant species followed by tamoxifen and metabolite Z. Small but significant amounts of the hydroxylated metabolites, trans-1(4-beta-hydroxyethoxyphenyl)-1,2-diphenylbut-1-ene (metabolite Y), 4-hydroxytamoxifen (metabolite B) and 4-hydroxy-N-desmethyltamoxifen (metabolite BX) were detected in most specimens. The ratios between the concentrations of tamoxifen and various metabolites were similar in tumour, brain and serum. This is the first report on the distribution of tamoxifen and metabolites into human brain and brain tumour, and the data form a basis for further investigation into the therapeutic effects of tamoxifen on brain metastases from breast cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lien, E., Wester, K., Lønning, P. et al. Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. Br J Cancer 63, 641–645 (1991). https://doi.org/10.1038/bjc.1991.147
Issue Date:
DOI: https://doi.org/10.1038/bjc.1991.147
This article is cited by
-
Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases
CNS Drugs (2023)
-
Leptomeningeal Metastases: New Opportunities in the Modern Era
Neurotherapeutics (2022)
-
Time interval between the diagnosis of breast cancer and brain metastases impacts prognosis after metastasis surgery
Journal of Neuro-Oncology (2022)
-
Advances in Management of Brain and Leptomeningeal Metastases
Current Neurology and Neuroscience Reports (2020)
-
Systemic therapy following craniotomy in patients with a solitary breast cancer brain metastasis
Breast Cancer Research and Treatment (2020)